APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Cancer Vaccine

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Selected research

Market Structure

Global Peptide Cancer Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026191 pages

Choose your research edition.

Industry ResearchPeptide Cancer Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Cancer Vaccine Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Peptide Cancer Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Cancer Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Cancer Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.

USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.

Read the full market overview

Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.

This report provides an overview of the global Peptide Cancer Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Cancer Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Cancer Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Cancer Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Cancer Vaccine Segment by Company

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

Peptide Cancer Vaccine Segment by Pipeline

ITK-1

GRN-1201

TPIV200

TPIV110

UV1

Galinpepimut-S

TARP 27-35

HER-Vaxx

Vx-001

Others

Peptide Cancer Vaccine Segment by Application

Breast Cancer

Lung Cancer

Melanoma

Prostate Cancer

Others

Peptide Cancer Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Cancer Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Peptide Cancer Vaccine Industry Trends Table 2. Peptide Cancer Vaccine Industry Drivers Table 3. Peptide Cancer Vaccine Industry Opportunities and Challenges Table 4. Peptide Cancer Vaccine Industry Restraints Table 5. Global Peptide Cancer Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Peptide Cancer Vaccine Sales by Manufacturers (K Doses) & (2021-2026) Table 8. Global Peptide Cancer Vaccine Sales Market Share by Manufacturers Table 9. Global Peptide Cancer Vaccine Average Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 10. Global Peptide Cancer Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Peptide Cancer Vaccine Manufacturers, Product Type & Application Table 13. Global Peptide Cancer Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Cancer Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of ITK-1 Table 17. Major Manufacturers of GRN-1201 Table 18. Major Manufacturers of TPIV200 Table 19. Major Manufacturers of TPIV110 Table 20. Major Manufacturers of UV1 Table 21. Major Manufacturers of Galinpepimut-S Table 22. Major Manufacturers of TARP 27-35 Table 23. Major Manufacturers of HER-Vaxx Table 24. Major Manufacturers of Vx-001 Table 25. Major Manufacturers of Others Table 26. Global Peptide Cancer Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Doses) Table 27. Global Peptide Cancer Vaccine Sales by Type (2021-2026) & (K Doses) Table 28. Global Peptide Cancer Vaccine Sales by Type (2027-2032) & (K Doses) Table 29. Global Peptide Cancer Vaccine Sales Market Share by Type (2021-2026) Table 30. Global Peptide Cancer Vaccine Sales Market Share by Type (2027-2032) Table 31. Global Peptide Cancer Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Doses) Table 32. Global Peptide Cancer Vaccine Revenue by Type (2021-2026) & (K Doses) Table 33. Global Peptide Cancer Vaccine Revenue by Type (2027-2032) & (K Doses) Table 34. Global Peptide Cancer Vaccine Revenue Market Share by Type (2021-2026) Table 35. Global Peptide Cancer Vaccine Revenue Market Share by Type (2027-2032) Table 36. Major Manufacturers of Breast Cancer Table 37. Major Manufacturers of Lung Cancer Table 38. Major Manufacturers of Melanoma Table 39. Major Manufacturers of Prostate Cancer Table 40. Major Manufacturers of Others Table 41. Global Peptide Cancer Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Doses) Table 42. Global Peptide Cancer Vaccine Sales by Application (2021-2026) & (K Doses) Table 43. Global Peptide Cancer Vaccine Sales by Application (2027-2032) & (K Doses) Table 44. Global Peptide Cancer Vaccine Sales Market Share by Application (2021-2026) Table 45. Global Peptide Cancer Vaccine Sales Market Share by Application (2027-2032) Table 46. Global Peptide Cancer Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Doses) Table 47. Global Peptide Cancer Vaccine Revenue by Application (2021-2026) & (K Doses) Table 48. Global Peptide Cancer Vaccine Revenue by Application (2027-2032) & (K Doses) Table 49. Global Peptide Cancer Vaccine Revenue Market Share by Application (2021-2026) Table 50. Global Peptide Cancer Vaccine Revenue Market Share by Application (2027-2032) Table 51. Global Peptide Cancer Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 52. Global Peptide Cancer Vaccine Sales by Region (2021-2026) & (K Doses) Table 53. Global Peptide Cancer Vaccine Sales Market Share by Region (2021-2026) Table 54. Global Peptide Cancer Vaccine Sales Forecasted by Region (2027-2032) & (K Doses) Table 55. Global Peptide Cancer Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 56. North America Peptide Cancer Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 57. North America Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses) Table 58. North America Peptide Cancer Vaccine Sales by Country (2027-2032) & (K Doses) Table 59. Europe Peptide Cancer Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 60. Europe Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses) Table 61. Europe Peptide Cancer Vaccine Sales by Country (2027-2032) & (K Doses) Table 62. Asia Pacific Peptide Cancer Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 63. Asia Pacific Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses) Table 64. Asia Pacific Peptide Cancer Vaccine Sales by Country (2027-2032) & (K Doses) Table 65. South America, Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 66. South America, Middle East and Africa Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses) Table 67. South America, Middle East and Africa Peptide Cancer Vaccine Sales by Country (2027-2032) & (K Doses) Table 68. Global Peptide Cancer Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 69. Global Peptide Cancer Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 70. Global Peptide Cancer Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 71. Global Peptide Cancer Vaccine Revenue Market Share by Region (2021-2026) Table 72. Global Peptide Cancer Vaccine Revenue Market Share by Region (2027-2032) Table 73. Boston Biomedical Company Information Table 74. Boston Biomedical Business Overview Table 75. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Boston Biomedical Peptide Cancer Vaccine Product Portfolio Table 77. Boston Biomedical Recent Development Table 78. Ultimovacs Company Information Table 79. Ultimovacs Business Overview Table 80. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Ultimovacs Peptide Cancer Vaccine Product Portfolio Table 82. Ultimovacs Recent Development Table 83. BrightPath Biotherapeutics Company Information Table 84. BrightPath Biotherapeutics Business Overview Table 85. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio Table 87. BrightPath Biotherapeutics Recent Development Table 88. TapImmune Company Information Table 89. TapImmune Business Overview Table 90. TapImmune Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. TapImmune Peptide Cancer Vaccine Product Portfolio Table 92. TapImmune Recent Development Table 93. Immatics Company Information Table 94. Immatics Business Overview Table 95. Immatics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Immatics Peptide Cancer Vaccine Product Portfolio Table 97. Immatics Recent Development Table 98. Sellas Company Information Table 99. Sellas Business Overview Table 100. Sellas Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sellas Peptide Cancer Vaccine Product Portfolio Table 102. Sellas Recent Development Table 103. Imugene Company Information Table 104. Imugene Business Overview Table 105. Imugene Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Imugene Peptide Cancer Vaccine Product Portfolio Table 107. Imugene Recent Development Table 108. VAXON Biotech Company Information Table 109. VAXON Biotech Business Overview Table 110. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. VAXON Biotech Peptide Cancer Vaccine Product Portfolio Table 112. VAXON Biotech Recent Development Table 113. Generex Biotechnology Company Information Table 114. Generex Biotechnology Business Overview Table 115. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio Table 117. Generex Biotechnology Recent Development Table 118. ISA Pharmaceuticals Company Information Table 119. ISA Pharmaceuticals Business Overview Table 120. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio Table 122. ISA Pharmaceuticals Recent Development Table 123. OncoTherapy Science Company Information Table 124. OncoTherapy Science Business Overview Table 125. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio Table 127. OncoTherapy Science Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Peptide Cancer Vaccine Distributors List Table 131. Peptide Cancer Vaccine Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Peptide Cancer Vaccine Product Image Figure 2. Global Peptide Cancer Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Cancer Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide Cancer Vaccine Sales (2021-2032) & (K Doses) Figure 5. Global Peptide Cancer Vaccine Average Price (USD/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. ITK-1 Image Figure 9. GRN-1201 Image Figure 10. TPIV200 Image Figure 11. TPIV110 Image Figure 12. UV1 Image Figure 13. Galinpepimut-S Image Figure 14. TARP 27-35 Image Figure 15. HER-Vaxx Image Figure 16. Vx-001 Image Figure 17. Others Image Figure 18. Global Peptide Cancer Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 19. Global Peptide Cancer Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Peptide Cancer Vaccine Sales Market Share by Type (2021-2032) Figure 21. Global Peptide Cancer Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 22. Global Peptide Cancer Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Peptide Cancer Vaccine Revenue Market Share by Type (2021-2032) Figure 24. Breast Cancer Image Figure 25. Lung Cancer Image Figure 26. Melanoma Image Figure 27. Prostate Cancer Image Figure 28. Others Image Figure 29. Global Peptide Cancer Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 30. Global Peptide Cancer Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 31. Global Peptide Cancer Vaccine Sales Market Share by Application (2021-2032) Figure 32. Global Peptide Cancer Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 33. Global Peptide Cancer Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 34. Global Peptide Cancer Vaccine Revenue Market Share by Application (2021-2032) Figure 35. North America Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 36. North America Peptide Cancer Vaccine Sales Market Share by Country (2021-2032) Figure 37. U.S. Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 38. Canada Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 39. Mexico Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 40. Europe Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 41. Europe Peptide Cancer Vaccine Sales Market Share by Country (2021-2032) Figure 42. Germany Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 43. France Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 44. U.K. Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 45. Italy Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 46. Netherlands Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 47. Asia Pacific Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 48. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Country (2021-2032) Figure 49. China Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 50. Japan Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 51. South Korea Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 52. Southeast Asia Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 53. India Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 54. Australia Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 55. South America, Middle East and Africa Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 56. South America, Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2021-2032) Figure 57. Brazil Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 58. South Africa Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 59. Saudi Arabia Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 60. Turkey Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 61. Argentina Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 62. UAE Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 63. Egypt Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 64. Chile Peptide Cancer Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 65. Global Peptide Cancer Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Global Peptide Cancer Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 67. North America Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Figure 68. North America Peptide Cancer Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Europe Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Figure 70. Europe Peptide Cancer Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Asia-Pacific Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Figure 72. Asia-Pacific Peptide Cancer Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 73. South America, Middle East and Africa Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Figure 74. South America, Middle East and Africa Peptide Cancer Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 75. Peptide Cancer Vaccine Value Chain Figure 76. Manufacturing Cost Structure Figure 77. Peptide Cancer Vaccine Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Years Considered Figure 81. Research Process Figure 82. Key Executives Interviewed

Scope & coverage.

Types
  • ITK-1
  • GRN-1201
  • TPIV200
  • TPIV110
  • UV1
  • Galinpepimut-S
  • TARP 27-35
  • HER-Vaxx
  • Vx-001
  • Others
Applications
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Others
Companies covered
  • Boston Biomedical
  • Ultimovacs
  • BrightPath Biotherapeutics
  • TapImmune
  • Immatics
  • Sellas
  • Imugene
  • VAXON Biotech
  • Generex Biotechnology
  • ISA Pharmaceuticals
  • OncoTherapy Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide Cancer Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Peptide Cancer Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Peptide Cancer Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Peptide Cancer Vaccine Market Dynamics
  1. 2.1 Peptide Cancer Vaccine Industry Trends
  2. 2.2 Peptide Cancer Vaccine Industry Drivers
  3. 2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
  4. 2.4 Peptide Cancer Vaccine Industry Restraints
3 Peptide Cancer Vaccine Market by Manufacturers
  1. 3.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Peptide Cancer Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Peptide Cancer Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Peptide Cancer Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Peptide Cancer Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier 3
4 Peptide Cancer Vaccine Market by Type
  1. 4.1 Peptide Cancer Vaccine Type Introduction
  2. 4.1.1 ITK-1
  3. 4.1.2 GRN-1201
  4. 4.1.3 TPIV200
  5. 4.1.4 TPIV110
  6. 4.1.5 UV1
  7. 4.1.6 Galinpepimut-S
  8. 4.1.7 TARP 27-35
  9. 4.1.8 HER-Vaxx
  10. 4.1.9 Vx-001
  11. 4.1.10 Others
  12. 4.2 Global Peptide Cancer Vaccine Sales by Type
  13. 4.2.1 Global Peptide Cancer Vaccine Sales by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Peptide Cancer Vaccine Sales by Type (2021-2032)
  15. 4.2.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2021-2032)
  16. 4.3 Global Peptide Cancer Vaccine Revenue by Type
  17. 4.3.1 Global Peptide Cancer Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Peptide Cancer Vaccine Revenue by Type (2021-2032)
  19. 4.3.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2021-2032)
5 Peptide Cancer Vaccine Market by Application
  1. 5.1 Peptide Cancer Vaccine Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Lung Cancer
  4. 5.1.3 Melanoma
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 Others
  7. 5.2 Global Peptide Cancer Vaccine Sales by Application
  8. 5.2.1 Global Peptide Cancer Vaccine Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Peptide Cancer Vaccine Sales by Application (2021-2032)
  10. 5.2.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2021-2032)
  11. 5.3 Global Peptide Cancer Vaccine Revenue by Application
  12. 5.3.1 Global Peptide Cancer Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Peptide Cancer Vaccine Revenue by Application (2021-2032)
  14. 5.3.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2021-2032)
6 Global Peptide Cancer Vaccine Sales by Region
  1. 6.1 Global Peptide Cancer Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Cancer Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Cancer Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Peptide Cancer Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide Cancer Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Peptide Cancer Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Peptide Cancer Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Peptide Cancer Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Peptide Cancer Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Peptide Cancer Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Peptide Cancer Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Peptide Cancer Vaccine Revenue by Region
  1. 7.1 Global Peptide Cancer Vaccine Revenue by Region
  2. 7.1.1 Global Peptide Cancer Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Peptide Cancer Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Peptide Cancer Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Peptide Cancer Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Peptide Cancer Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Peptide Cancer Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Peptide Cancer Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Peptide Cancer Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Peptide Cancer Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Peptide Cancer Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Peptide Cancer Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Peptide Cancer Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Boston Biomedical
  2. 8.1.1 Boston Biomedical Company Information
  3. 8.1.2 Boston Biomedical Business Overview
  4. 8.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
  6. 8.1.5 Boston Biomedical Recent Developments
  7. 8.2 Ultimovacs
  8. 8.2.1 Ultimovacs Company Information
  9. 8.2.2 Ultimovacs Business Overview
  10. 8.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
  12. 8.2.5 Ultimovacs Recent Developments
  13. 8.3 BrightPath Biotherapeutics
  14. 8.3.1 BrightPath Biotherapeutics Company Information
  15. 8.3.2 BrightPath Biotherapeutics Business Overview
  16. 8.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
  18. 8.3.5 BrightPath Biotherapeutics Recent Developments
  19. 8.4 TapImmune
  20. 8.4.1 TapImmune Company Information
  21. 8.4.2 TapImmune Business Overview
  22. 8.4.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
  24. 8.4.5 TapImmune Recent Developments
  25. 8.5 Immatics
  26. 8.5.1 Immatics Company Information
  27. 8.5.2 Immatics Business Overview
  28. 8.5.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
  30. 8.5.5 Immatics Recent Developments
  31. 8.6 Sellas
  32. 8.6.1 Sellas Company Information
  33. 8.6.2 Sellas Business Overview
  34. 8.6.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
  36. 8.6.5 Sellas Recent Developments
  37. 8.7 Imugene
  38. 8.7.1 Imugene Company Information
  39. 8.7.2 Imugene Business Overview
  40. 8.7.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
  42. 8.7.5 Imugene Recent Developments
  43. 8.8 VAXON Biotech
  44. 8.8.1 VAXON Biotech Company Information
  45. 8.8.2 VAXON Biotech Business Overview
  46. 8.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
  48. 8.8.5 VAXON Biotech Recent Developments
  49. 8.9 Generex Biotechnology
  50. 8.9.1 Generex Biotechnology Company Information
  51. 8.9.2 Generex Biotechnology Business Overview
  52. 8.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
  54. 8.9.5 Generex Biotechnology Recent Developments
  55. 8.10 ISA Pharmaceuticals
  56. 8.10.1 ISA Pharmaceuticals Company Information
  57. 8.10.2 ISA Pharmaceuticals Business Overview
  58. 8.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
  60. 8.10.5 ISA Pharmaceuticals Recent Developments
  61. 8.11 OncoTherapy Science
  62. 8.11.1 OncoTherapy Science Company Information
  63. 8.11.2 OncoTherapy Science Business Overview
  64. 8.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
  66. 8.11.5 OncoTherapy Science Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Cancer Vaccine Value Chain Analysis
  2. 9.1.1 Peptide Cancer Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Cancer Vaccine Production Mode & Process
  6. 9.2 Peptide Cancer Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Cancer Vaccine Distributors
  9. 9.2.3 Peptide Cancer Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst